Specialized Anti-Mycobacterial Solutions for High-Security and Extreme Environments

Publication ID: 24-11857521_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Anti-Mycobacterial Solutions for High-Security and Extreme Environments,” Published Technical Disclosure No. 24-11857521_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857521_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,521.

Summary of the Inventive Concept

This inventive concept adapts the original anti-mycobacterial drug concept for specific, narrow markets and unique operational environments, addressing the need for effective treatments in high-security settings, disaster relief situations, and extreme weather conditions.

Background and Problem Solved

The original anti-mycobacterial drug concept, while effective, has limitations in terms of its applicability in high-security environments, disaster relief situations, and extreme weather conditions. This new inventive concept addresses these limitations by providing specialized solutions tailored to these specific contexts.

Detailed Description of the Inventive Concept

The inventive concept comprises a series of oligo(carbamoylated guanidine) (OCG) structures, wherein n is an integer ranging from 3 to 50, X is an alkylene, and Y is a linear or cyclic alkylene. These OCGs are designed to be effective against mycobacterial infections in high-security environments, disaster relief situations, and extreme weather conditions. The inventive concept also includes pharmaceutical compositions, methods of treatment, and systems for delivering these OCGs in these specialized contexts.

Novelty and Inventive Step

The novelty of this inventive concept lies in its adaptation of the original anti-mycobacterial drug concept for specific, narrow markets and unique operational environments. The inventive step is the recognition of the need for specialized solutions in these contexts and the development of OCG structures and delivery systems tailored to these needs.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include varying the structure of the OCGs, using different alkylene or arylene groups, or incorporating additional functional groups to enhance efficacy or stability. Variations could also include different delivery systems, such as topical compositions or injectable formulations, to suit specific operational environments.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of high-security environments, disaster relief, and extreme weather conditions. Target markets could include government agencies, humanitarian organizations, and private companies operating in these specialized contexts.

CPC Classifications

SectionClassGroup
A A61 A61K31/17
A A61 A61K31/133
A A61 A61K31/277
A A61 A61K31/4409
A A61 A61K31/47
A A61 A61K31/496
A A61 A61K31/498
A A61 A61K31/4965
A A61 A61K31/5377
A A61 A61P31/06
C C07 C07C279/12
C C07 C07D295/215
C C08 C08G65/00
C C08 C08G71/02
C C07 C07C2601/16

Field of Art

Pharmaceutical chemistry, specifically anti-mycobacterial drug development, involving organic synthesis, medicinal chemistry, and drug design for infectious disease treatment

Person of Ordinary Skill (PHOSITA) Profile

A researcher with a PhD in pharmaceutical chemistry or organic synthesis, experienced in drug design, structure-activity relationships, and modification of therapeutic compounds, familiar with synthetic organic chemistry techniques and mycobacterial infection treatment strategies

Obviousness Rationale

A PHOSITA would recognize that the PTD's specialized environmental adaptations represent predictable variations of the source patent's core oligo(carbamoylated guanidine) structure. The modifications involve routine design choices in drug delivery and formulation that would be obvious to a skilled practitioner seeking to optimize anti-mycobacterial treatments for specific operational contexts. The fundamental molecular structure remains substantially unchanged, with variations primarily addressing implementation and delivery strategies.

Obvious Combinations & Variations

Source Patent Element
Oligo(carbamoylated guanidine) with n ranging from 3 to 50
PTD Variation
Adapting OCG structure for high-security and disaster relief environments
Obviousness Reasoning
Routine application of known molecular structure to specialized use cases, representing a predictable extension of existing drug design principles
Source Patent Element
Pharmaceutical composition of anti-mycobacterial compounds
PTD Variation
Developing carrier materials resistant to high-temperature degradation
Obviousness Reasoning
Known technique of modifying pharmaceutical formulations to enhance stability in extreme environmental conditions, representing a standard design optimization approach
Source Patent Element
Base OCG molecular structure with variable X and Y substituents
PTD Variation
Creating topical and portable delivery systems for specialized environments
Obviousness Reasoning
Predictable variation in drug delivery methods using standard pharmaceutical engineering approaches, representing an obvious solution to context-specific treatment challenges
Source Patent Element
Anti-mycobacterial drug targeting Mycobacterium tuberculosis
PTD Variation
Developing targeted delivery systems for high-security and disaster relief scenarios
Obviousness Reasoning
Logical extension of existing treatment strategies to address specific operational requirements, utilizing known pharmaceutical design principles
Source Patent Element
Chemical structure with modifiable alkylene and linear/cyclic substituents
PTD Variation
Incorporating alternative functional groups to enhance efficacy and stability
Obviousness Reasoning
Routine chemical modification representing a predictable approach to optimizing drug performance, well within a PHOSITA's standard problem-solving capabilities
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this Published Technical Disclosure would have been obvious to a Person Having Ordinary Skill In The Art at the time of invention, as they represent predictable extensions of the foundational teachings in US Patent 11857521, involving routine pharmaceutical engineering techniques and standard molecular modifications within the anti-mycobacterial drug development domain.

Original Patent Information

Patent NumberUS 11,857,521
TitleAnti-mycobacterial drugs
Assignee(s)The Florida International University Board of Trustees